CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.34B
This Quarter Return
+56.41%
1 Year Return
+85.27%
3 Year Return
+2,244.39%
5 Year Return
+2,846.94%
10 Year Return
+51,155.97%
AUM
$1.76B
AUM Growth
+$1.76B
(+16%)
Cap. Flow
-$130M
Cap. Flow
% of AUM
-7.41%
Top 10 Holdings %
Top 10 Hldgs %
61.02%
Holding
81
New
8
Increased
13
Reduced
7
Closed
19
Top Buys
| 1 |
MoonLake Immunotherapeutics
MLTX
|
$63.7M |
| 2 |
Zentalis Pharmaceuticals
ZNTL
|
$30.9M |
| 3 |
CBAY
Cymabay Therapeutics
CBAY
|
$27.7M |
| 4 |
EyePoint Pharmaceuticals
EYPT
|
$25.9M |
| 5 |
Vaxcyte
PCVX
|
$19.5M |
Top Sells
| 1 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
$178M |
| 2 |
Pliant Therapeutics
PLRX
|
$38.4M |
| 3 |
89bio
ETNB
|
$27.5M |
| 4 |
RAIN
Rain Oncology Inc. Common Stock
RAIN
|
$26M |
| 5 |
Monte Rosa Therapeutics
GLUE
|
$22.5M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
MoonLake Immunotherapeutics
MLTX
$3.54B
| $415M | 23.26% | 8,142,100 +1,249,999 | +18% | +$63.7M |
|
|
AMAM
2
DELISTED
Ambrx Biopharma, Inc. Common Stock
AMAM
| $158M | 8.87% | 9,616,155 +1,116,155 | +13% | +$18.4M |
|
3
Apellis Pharmaceuticals
APLS
$3.48B
| $119M | 6.69% | 1,310,000 -50,000 | -4% | -$4.56M |
|
4
Biomea Fusion
BMEA
$116M
| $78.4M | 4.39% | 3,570,872 | – | – |
|
5
BridgeBio Pharma
BBIO
$9.89B
| $71.7M | 4.02% | 4,169,179 -388,235 | -9% | -$6.68M |
|
6
Arcellx
ACLX
$3.85B
| $63.2M | 3.54% | 2,000,000 +400,000 | +25% | +$12.6M |
|
7
Immuneering
IMRX
$245M
| $42.6M | 2.39% | 4,204,364 +1,818,183 | +76% | +$18.4M |
|
|
CBAY
8
DELISTED
Cymabay Therapeutics
CBAY
| $41.6M | 2.33% | 3,800,000 +2,528,571 | +199% | +$27.7M |
|
9
Protagonist Therapeutics
PTGX
$3.67B
| $41.4M | 2.32% | 1,500,000 -200,000 | -12% | -$5.52M |
|
10
Enliven Therapeutics
ELVN
$1.2B
| $39.5M | 2.21% | 1,936,133 | – | – |
|
|
11
Vaxcyte
PCVX
$4B
| $33.2M | 1.86% | 665,000 +390,000 | +142% | +$19.5M |
|
12
Design Therapeutics
DSGN
$315M
| $32.4M | 1.82% | 5,150,000 | – | – |
|
|
13
Zentalis Pharmaceuticals
ZNTL
$122M
| $30.9M | 1.73% | +1,095,000 | New | +$30.9M |
|
14
Erasca
ERAS
$445M
| $29.8M | 1.67% | 10,813,246 | – | – |
|
15
Avidity Biosciences
RNA
$5.99B
| $29M | 1.62% | 2,612,115 | – | – |
|
16
Cabaletta Bio
CABA
$133M
| $28.7M | 1.61% | 2,221,739 +400,000 | +22% | +$5.16M |
|
|
17
EyePoint Pharmaceuticals
EYPT
$797M
| $27.8M | 1.56% | 3,200,000 +2,974,935 | +1,322% | +$25.9M |
|
18
Olema Pharmaceuticals
OLMA
$375M
| $27.8M | 1.56% | 3,082,000 | – | – |
|
|
JBIO
19
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $26.8M | 1.5% | 1,561,696 | – | – |
|
20
Tarsus Pharmaceuticals
TARS
$2.47B
| $25.7M | 1.44% | 1,421,422 | – | – |
|
|
21
89bio
ETNB
$1.34B
| $25.6M | 1.43% | 1,350,000 -1,450,000 | -52% | -$27.5M |
|
22
Axsome Therapeutics
AXSM
$6.05B
| $24.4M | 1.37% | 340,000 +40,000 | +13% | +$2.87M |
|
23
Structure Therapeutics
GPCR
$1.11B
| $24M | 1.34% | 576,373 | – | – |
|
24
Edgewise Therapeutics
EWTX
$1.51B
| $22.8M | 1.28% | 2,946,887 | – | – |
|
25
Viridian Therapeutics
VRDN
$1.5B
| $20.2M | 1.13% | 850,000 | – | – |
|